| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant nivolumab for the management of pathological residual disease in esophageal or junctional tumors: a word of caution
|
Garg, P.K.
|
|
|
32 |
9 |
p. 1189-1190
|
artikel
|
| 2 |
Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
|
Rao, S.
|
|
|
32 |
9 |
p. 1087-1100
|
artikel
|
| 3 |
Association between HER2 status in residual disease and sensitivity to trastuzumab emtansine
|
Altundag, K.
|
|
|
32 |
9 |
p. 1191
|
artikel
|
| 4 |
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer ☆
|
Bardia, A.
|
|
|
32 |
9 |
p. 1148-1156
|
artikel
|
| 5 |
Characteristics of residual invasive breast cancer after neoadjuvant therapy in the KATHERINE study
|
Mamounas, E.P.
|
|
|
32 |
9 |
p. 1191-1192
|
artikel
|
| 6 |
Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set
|
Klein, E.A.
|
|
|
32 |
9 |
p. 1167-1177
|
artikel
|
| 7 |
Corrigendum to ‘Measures of body fatness and height in early and mid-to-late adulthood and prostate cancer: risk and mortality in The Pooling Project of Prospective Studies of Diet and Cancer’
|
Genkinger, J.M.
|
|
|
32 |
9 |
p. 1201
|
artikel
|
| 8 |
Co-targeting the VEGF axis and immune checkpoints in NSCLC: back to the future
|
Saw, S.P.L.
|
|
|
32 |
9 |
p. 1075-1076
|
artikel
|
| 9 |
Deep learning for diagnosis and survival prediction in soft tissue sarcoma
|
Foersch, S.
|
|
|
32 |
9 |
p. 1178-1187
|
artikel
|
| 10 |
Editorial Board
|
|
|
|
32 |
9 |
p. iii
|
artikel
|
| 11 |
Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust
|
Piccart, M.J.
|
|
|
32 |
9 |
p. 1077-1082
|
artikel
|
| 12 |
Genome instability and success of checkpoint inhibitors: form and levels matter
|
Derks, S.
|
|
|
32 |
9 |
p. 1073-1074
|
artikel
|
| 13 |
Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma ☆
|
Shitara, K.
|
|
|
32 |
9 |
p. 1127-1136
|
artikel
|
| 14 |
Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer
|
Sugawara, S.
|
|
|
32 |
9 |
p. 1137-1147
|
artikel
|
| 15 |
Practical considerations in screening for genetic alterations in cholangiocarcinoma
|
Bekaii-Saab, T.S.
|
|
|
32 |
9 |
p. 1111-1126
|
artikel
|
| 16 |
Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab
|
Fabrizio, D.
|
|
|
32 |
9 |
p. 1193-1194
|
artikel
|
| 17 |
Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al.
|
McGrail, D.J.
|
|
|
32 |
9 |
p. 1194-1197
|
artikel
|
| 18 |
Reply to the letter to the editor: adjuvant nivolumab for the management of the pathological residual disease in esophageal or junctional tumors: a word of caution by P.K. Garg, R. Kumar and P. Dixit
|
Smyth, E.C.
|
|
|
32 |
9 |
p. 1190-1191
|
artikel
|
| 19 |
Right to Try, expanded access use, Project Facilitate, and clinical trial reform
|
Reddy, N.K.
|
|
|
32 |
9 |
p. 1083-1086
|
artikel
|
| 20 |
Table of Contents
|
|
|
|
32 |
9 |
p. i-ii
|
artikel
|
| 21 |
Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches
|
Reck, M.
|
|
|
32 |
9 |
p. 1101-1110
|
artikel
|
| 22 |
TMB cut-offs fail to predict benefit of PD-1 blockade in gastroesophageal adenocarcinoma in KEYNOTE-061
|
Foote, M.B.
|
|
|
32 |
9 |
p. 1188-1189
|
artikel
|
| 23 |
Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial ☆
|
Hamid, A.A.
|
|
|
32 |
9 |
p. 1157-1166
|
artikel
|
| 24 |
Use of clinical selection for intensification of therapy in metastatic castrate-resistant prostate cancer
|
Iacovelli, R.
|
|
|
32 |
9 |
p. 1192-1193
|
artikel
|
| 25 |
VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC
|
Schmid, P.
|
|
|
32 |
9 |
p. 1198-1200
|
artikel
|
Tijdschrift beschrijving